Home > PORTAL > about Us > Presentation >
Learn how SPIN got started
SPIN – Skin Inflammation & Psoriasis International Network was initiated in 2004 as PIN – Psoriasis International Network by the FRT - Fondation René Touraine, a non-profit and a non-governmental organisation dedicated to support therapeutic progress in dermatology by fostering international collaborations.
After several European meetings on psoriasis held in Italy every 2 or 3 years, the FRT and Prof. Louis Dubertret organised the European Congress on Psoriasis - PSO 2004 in Paris, which acquired a great international dimension, with over 600 participants from 40 different countries. Following the PSO 2004 Congress, many participants showed great interest in developing networking activities in the field of psoriasis.
The founding meeting of the former PIN was held in Paris (Nov 18, 2005) between 20 countries willing to develop national psoriasis groups and willing to connect these groups into an international network. 11 countries were able to send a representative and 9 additional countries expressed a strong interest but were unable to come. The President of EUROPSO, the European federation of psoriasis associations, participated as well in the founding meeting.
This founding meeting formalised the international collaborations in the field of psoriasis started with the PSO 2004 Congress, creating thus the Psoriasis International Network. To develop this international network, it was proposed to:
• set up a website: www.psoriasis-international.org (now www.spindermatology.org!)
• organise every 3 years an International Congress on Psoriasis in Paris
• publish regular newsletters and "Focus On”
In 2011, a Scientific Committee was created to steer the scientific development of the network by proposing international collaborative projects, contributing to continuing medical training in psoriasis and supporting the development of national and regional psoriasis networks.
The network has grown ever since, gathering around 4700 healthcare professionals involved in the management of psoriasis from some 100 countries, 330 dermatology centres as well as 43 patient organisations. Since 2004, PIN has successfully:
• organised 5 international congresses on psoriasis and educational symposia during other dermatology meetings
• built a worldwide directory listing psoriasis medical resources for patients
• provided organisational support to the development of dedicated outpatient consultations at the local level
• fostered the development of national and regional networks on psoriasis
• carried out international studies on the current practice of the use of methotrexate and phototherapy in the treatment of psoriasis
• initiated a worldwide survey on the use of therapeutic patient education in psoriasis with the aim of developing a toolbox
• collaborated with the EADV Psoriasis Task Force since 2005.
In 2016, it was decided by the FRT Board of Directors to broaden the scope of the PIN to include other major chronic inflammatory skin diseases. This would allow to benefit from the benchmark of PIN’s actions and achievements in psoriasis and put it to the service of other diseases. With this change, we hope to transfer the know-how acquired on psoriasis (highest standard in issues such as quality of life, high burden and co-morbidities) and build on the collaborations made possible via the PIN network and expand them to other major chronic skin inflammatory diseases.
Following this decision, the former PIN Scientific Committee has decided to change the name of the network to SPIN – Skin Inflammation & Psoriasis International Network. On an operational level, the Committee decided to broaden the network’s scope progressively, one chronic inflammatory skin disease at a time. Starting in 2017, the new SPIN will cover psoriasis and expand its activities to atopic dermatitis.
SPIN Presentation
Recent news
- 2019/10/29 Focus on...
- 2019/08/12 Focus on...
Latin American Clinical Practice Guidelines on the Systemic Treatment of Psoriasis
- 2019/06/03 Focus on...
- 2019/05/21 Focus on...
Prof Nelida Aurora Raimondo
News from the web office
- 2016/10/29
- 2016/05/26
- 2016/02/20
Events
- 2019/04/18 Focus on...
- 2018/02/21
News from medical groups
- 2018/04/18
- 2017/06/21
News from patients associations
- 2017/02/08
- 2016/05/26
Recent publications on Psoriasis and Atopic Dermatitis
on Psoriasis
Screening for cardiovascular comorbidity in United States outpatients with psoriasis, hidradenitis, and atopic dermatitis.
Arch Dermatol Res.
2021 Apr , 313, (3):163-171.
Psoriasis, hidradenitis, and atopic dermatitis (AD) are associated with increased cardiometabolic comorbidities. Yet, little is known about screening rates for cardiometabolic comorbidities in patients with these disorders. The objective of this study is to determine rates and predictors of cardiovascular screening among patients with psoriasis, AD, and hidradenitis in the United States. Data from the 2006-2015 National Ambulatory Medical Care Survey were analyzed, including 67,581 (...)
see on pubmed
Nanoliposomes@Transcutol for Skin Delivery of 8-Methoxypsoralen.
Sinico C et al.
Nanoliposomes@Transcutol for Skin Delivery of 8-Methoxypsoralen.
J Nanosci Nanotechnol.
2021 May 01, 21, (5):2901-2906.
8-methoxypsoralen is the most common drug in psoralen plus ultraviolet light irradiation therapy for the treatment of severe psoriasis. Despite of the efficacy, its classic oral administration leads to several serious adverse effects. However, the topical psoralen application produces a drug skin accumulation lower than that obtained by oral administration, due to the drug low skin permeability. In this paper, 8-methoxypsoralen loaded Penetration Enhancer-containing Vesicles were prepared (...)
see on pubmed
Catalpol ameliorates psoriasis-like phenotypes via SIRT1 mediated suppression of NF-κB and MAPKs signaling pathways.
Bioengineered.
2021 Dec , 12, (1):183-195.
Psoriasis is a chronic inflammatory skin disease that affects approximately 2% of worldwide population, and causing long-term troubles to the patients. Therefore, it is urgent to develop safe and effective therapeutic drugs. Catalpol is a natural iridoid glucoside, that has several remarkable pharmacological effects, however, whether catalpol can alleviated psoriasis has not been explored. The goal of the present work is to study the role of catalpol in psoriasis in vivo and in vitro. (...)
see on pubmed
on Atopic Dermatitis
Screening for cardiovascular comorbidity in United States outpatients with psoriasis, hidradenitis, and atopic dermatitis.
Arch Dermatol Res.
2021 Apr , 313, (3):163-171.
Psoriasis, hidradenitis, and atopic dermatitis (AD) are associated with increased cardiometabolic comorbidities. Yet, little is known about screening rates for cardiometabolic comorbidities in patients with these disorders. The objective of this study is to determine rates and predictors of cardiovascular screening among patients with psoriasis, AD, and hidradenitis in the United States. Data from the 2006-2015 National Ambulatory Medical Care Survey were analyzed, including 67,581 (...)
see on pubmed
Qingxue jiedu formulation ameliorated DNFB-induced atopic dermatitis by inhibiting STAT3/MAPK/NF-κB signaling pathways.
J Ethnopharmacol.
2021 Apr 24, 270:113773.
Qingxue jiedu Formulation (QF) is composed of two classic prescriptions which have been clinically used for more than 5 centuries and appropriately modified through basic theory of traditional Chinese medicine for treating various skin inflammation such as atopic dermatitis (AD), acute dermatitis and rash. Although QF possesses a prominent clinical therapeutic effect, seldom pharmacological studies on its anti-AD activity are (...)
see on pubmed
Methicillin-resistant from infected skin lesions present several virulence genes and are associated with the CC30 in Brazilian children with atopic dermatitis.
Virulence.
2021 Dec , 12, (1):260-269.
Atopic dermatitis (AD) is a chronic inflammatory skin disease and colonization by may affect up to 100% of these patients. Virulent and resistant isolates can worsen AD patient clinical condition and jeopardize the treatment. We aimed to detect virulence genes and to evaluate the biofilm production of isolates from infected skin lesions of children with AD. Methicillin resistance was detected by phenotypic and molecular tests and the virulence genes were detected by PCR. Biofilm formation (...)
see on pubmed